Kaveri Pohlman
Stock Analyst at BTIG
(1.14)
# 2,575
Out of 4,414 analysts
19
Total ratings
36.84%
Success rate
-13.34%
Average return
Main Sectors:
Top Industries:
14 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGEM Cullinan Oncology | Maintains: Buy | $20 → $30 | $27.58 | +8.77% | 2 | Apr 17, 2024 | |
| XNCR Xencor | Maintains: Buy | $56 → $38 | $23.63 | +60.81% | 1 | Apr 16, 2024 | |
| NUVB Nuvation Bio | Upgrades: Buy | $5 | $3.27 | +52.91% | 2 | Mar 26, 2024 | |
| JANX Janux Therapeutics | Initiates: Buy | $62 | $62.43 | -0.69% | 1 | Mar 21, 2024 | |
| MGNX MacroGenics | Maintains: Buy | $12 → $24 | $15.22 | +57.69% | 2 | Mar 4, 2024 | |
| PYXS Pyxis Oncology | Initiates: Buy | $8 | $4.41 | +81.41% | 1 | Feb 9, 2024 | |
| EXEL Exelixis | Initiates: Buy | $27 | $22.12 | +22.06% | 1 | Dec 19, 2023 | |
| GMAB Genmab | Maintains: Buy | $44 → $46 | $27.72 | +65.95% | 2 | Oct 13, 2023 | |
| RCUS Arcus Biosciences | Reiterates: Buy | $70 | $15.50 | +351.61% | 1 | Aug 23, 2023 | |
| STTK Shattuck Labs | Initiates: Buy | $12 | $11.10 | +8.11% | 1 | Aug 31, 2022 | |
| CTMX CytomX Therapeutics | Maintains: Buy | $16 → $8 | $4.50 | +77.78% | 2 | Jul 7, 2022 | |
| NEXI NexImmune | Initiates: Buy | $125 | $3.12 | +3,906.41% | 1 | Jun 1, 2022 | |
| ONCT Oncternal Therapeutics | Initiates: Buy | $100 | $8.75 | +1,043.51% | 1 | Feb 24, 2022 | |
| SONN Sonnet BioTherapeutics Holdings | Maintains: Buy | $1,540 → $616 | $1.92 | +31,983.33% | 1 | Feb 9, 2022 |
Cullinan Oncology
Apr 17, 2024
Maintains: Buy
Price Target: $20 → $30
Current: $27.58
Upside: +8.77%
Xencor
Apr 16, 2024
Maintains: Buy
Price Target: $56 → $38
Current: $23.63
Upside: +60.81%
Nuvation Bio
Mar 26, 2024
Upgrades: Buy
Price Target: $5
Current: $3.27
Upside: +52.91%
Janux Therapeutics
Mar 21, 2024
Initiates: Buy
Price Target: $62
Current: $62.43
Upside: -0.69%
MacroGenics
Mar 4, 2024
Maintains: Buy
Price Target: $12 → $24
Current: $15.22
Upside: +57.69%
Pyxis Oncology
Feb 9, 2024
Initiates: Buy
Price Target: $8
Current: $4.41
Upside: +81.41%
Exelixis
Dec 19, 2023
Initiates: Buy
Price Target: $27
Current: $22.12
Upside: +22.06%
Genmab
Oct 13, 2023
Maintains: Buy
Price Target: $44 → $46
Current: $27.72
Upside: +65.95%
Arcus Biosciences
Aug 23, 2023
Reiterates: Buy
Price Target: $70
Current: $15.50
Upside: +351.61%
Shattuck Labs
Aug 31, 2022
Initiates: Buy
Price Target: $12
Current: $11.10
Upside: +8.11%
CytomX Therapeutics
Jul 7, 2022
Maintains: Buy
Price Target: $16 → $8
Current: $4.50
Upside: +77.78%
NexImmune
Jun 1, 2022
Initiates: Buy
Price Target: $125
Current: $3.12
Upside: +3,906.41%
Oncternal Therapeutics
Feb 24, 2022
Initiates: Buy
Price Target: $100
Current: $8.75
Upside: +1,043.51%
Sonnet BioTherapeutics Holdings
Feb 9, 2022
Maintains: Buy
Price Target: $1,540 → $616
Current: $1.92
Upside: +31,983.33%